Insider Trading April 2, 2026

Xos Director Bernstein Disposes of 4,071 Shares in March Transaction

Sale occurs as XOS trades near its 52-week low amid mixed operational results and a milestone year for the company

By Nina Shah XOS
Xos Director Bernstein Disposes of 4,071 Shares in March Transaction
XOS

Director Stuart N. Bernstein sold 4,071 shares of Xos, Inc. common stock on March 31, 2026, in a trade totaling $6,693. The company reported a shift to profitability and positive cash flow for 2025 despite a drop in annual revenue; the shares have also been under recent pressure and are trading near a 52-week low.

Key Points

  • Director Stuart N. Bernstein sold 4,071 shares of Xos, Inc. on March 31, 2026, at prices between $1.64 and $1.662 for total proceeds of $6,693.
  • Following the sale Bernstein directly owns 94,087 shares, which include 62,377 unvested RSUs, and indirectly owns 4,133 shares through Bernstein Investment Partners LLC.
  • Xos reported first-time profitability and positive cash flow in 2025, delivering a record 328 units while annual revenue fell to $46 million from $56 million in 2024; the stock traded near a 52-week low and reacted positively in aftermarket trading.

Director Stuart N. Bernstein reported the sale of 4,071 shares of Xos, Inc. (NASDAQ: XOS) common stock on March 31, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The filing shows the shares were sold at prices between $1.64 and $1.662, producing gross proceeds of $6,693.

The transaction took place as the stock was trading close to its 52-week low of $1.60. Over the past week the share price has fallen roughly 15%, and it is down about 37% over the last six months, reflecting recent volatility in the market for the company’s equity.

After completing the March 31 sale, Bernstein retains direct ownership of 94,087 shares of Xos, Inc. That total includes 62,377 unvested Restricted Stock Units (RSUs). In addition to his direct holdings, Bernstein indirectly holds 4,133 shares through Bernstein Investment Partners LLC, where he is listed as the Managing Member.

The insider sale occurs against a backdrop of notable operational developments for Xos. The company reported it achieved profitability and positive cash flow for the first time in 2025. In that year Xos delivered a company-record 328 units, even as reported annual revenue declined to $46 million from $56 million in 2024. The company’s financial results prompted a positive reaction in aftermarket trading following the announcement.

Market participants and sell-side observers have been monitoring these developments closely. The move to profitability and the ability to produce positive cash flow are frequently cited metrics when assessing a company’s near-term financial stability. At the same time, the combination of deteriorating revenue and recent share-price weakness has contributed to heightened scrutiny of the company’s performance and valuation.

This filing adds to the public record on insider activity at Xos and provides an updated view of Bernstein’s stake following the March transaction. The Form 4 details and the company’s disclosed 2025 operating outcomes together offer investors and analysts additional data points as they assess Xos’s financial trajectory and market valuation.

Risks

  • Share-price volatility and recent declines - the stock is near its 52-week low of $1.60 and has fallen 15% over the past week and 37% over six months, which could affect investor sentiment in NASDAQ-listed small-cap equities.
  • Revenue contraction despite profitability - annual revenue decreased to $46 million from $56 million in 2024, introducing uncertainty about the sustainability of margins and growth.
  • Dependence on sustaining positive cash flow - while the company reported positive cash flow in 2025, maintaining that trajectory is uncertain and is a key variable for future operational stability.

More from Insider Trading

National CineMedia General Counsel Sells $36,680 in NCMI Stock Amid Recent Vesting Apr 2, 2026 Adaptive Biotechnologies COO Sells $553,693 in ADPT Stock as Options Are Exercised; Adeptus Posts Q4 Beat Apr 2, 2026 Zenas BioPharma Director Buys $70,197 in Stock as Company Advances Clinical and Financing Plans Apr 2, 2026 Accel Entertainment CEO Disposes of $497K in Stock as Company Posts Strong Q4 Results Apr 2, 2026 Axcelis CEO Executes $117K Sale; Company Posts Strong Quarter Amid Leadership Moves Apr 2, 2026